Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,338 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.
Miyamoto-Nagai Y, Mimura N, Tsukada N, Aotsuka N, Ri M, Katsuoka Y, Wakayama T, Suzuki R, Harazaki Y, Matsumoto M, Kumagai K, Miyake T, Ozaki S, Shono K, Tanaka H, Shimura A, Kuroda Y, Sunami K, Suzuki K, Yamashita T, Shimizu K, Murakami H, Abe M, Nakaseko C, Sakaida E. Miyamoto-Nagai Y, et al. Among authors: shimizu k. EJHaem. 2022 Jul 21;3(3):838-848. doi: 10.1002/jha2.534. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051061 Free PMC article.
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Ozaki S, et al. Among authors: shimizu k. J Cancer Res Clin Oncol. 2022 Jan;148(1):191-203. doi: 10.1007/s00432-021-03668-6. Epub 2021 Jun 2. J Cancer Res Clin Oncol. 2022. PMID: 34080068
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Suzuki K, Sunami K, Matsumoto M, Maki A, Shimada F, Suzuki K, Shimizu K. Suzuki K, et al. Among authors: shimizu k. Acta Haematol. 2021;144(3):264-274. doi: 10.1159/000508529. Epub 2020 Dec 4. Acta Haematol. 2021. PMID: 33279887 Free PMC article. Clinical Trial.
Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Kasamatsu T, et al. Among authors: shimizu k. Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19. Hematol Oncol. 2018. PMID: 30176173 Clinical Trial.
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Murakami H, et al. Among authors: shimizu k. Eur J Haematol. 2007 Sep;79(3):234-9. doi: 10.1111/j.1600-0609.2007.00908.x. Epub 2007 Jul 26. Eur J Haematol. 2007. PMID: 17655699 Clinical Trial.
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Ozaki S, et al. Among authors: shimizu k. Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5. Ann Hematol. 2016. PMID: 27044390 Clinical Trial.
7,338 results